Philips and Vithas Sign a 5 Year Strategic Agreement

January 25, 2021

Philips and Vithas Group, Spain’s second-largest private healthcare group, today signed a 5-year innovation and collaboration agreement in the areas of precision diagnosis and image-guided intervention.

The agreement will allow Vithas Group hospitals and medical centers to benefit from the latest innovations in diagnostic imaging technology, healthcare informatics, and equipment for minimally-invasive interventional procedures. Vithas Group hospitals and clinics offer healthcare and advanced medical care in thirteen provinces in seven autonomous regions of Spain.

Under the terms of the agreement, Philips will deliver a technology management model that ensures Vithas Group’s current and future health technology needs in the relevant areas are met, together with the associated maintenance, updating, and equipment and system renewal needs. This management model will enable Vithas Group to achieve better results, provide optimal care at lower cost, and deliver a better experience for its patients and healthcare professionals.

In addition, Vithas will become a ‘reference technology partner’ for Philips in Spain, which means that its hospitals and medical centers will be able to implement new advances and innovations developed by Philips, before standard commercialization of these solutions in Spain.

“This new alliance with Philips integrates cutting-edge technology, healthcare excellence, innovation, and research, which are the fundamental pillars on which we support our commitment to always seek the best experience for our patients,” said Dr. Pedro Rico, CEO of Vithas Group. “Furthermore, our professionals will have the most advanced technological solutions at all times, which will reinforce the quality of care and facilitate their research work.”

“We are very excited about the trust placed in Philips and convinced that, through this collaboration agreement, Vithas will have all the technology and innovation necessary to continue achieving the best health results and the best experience for its patients and its healthcare professionals,” said Juan Sanabria, President of Philips Ibérica. “We are proud to become the technological partner and strategic ally of a group as important as Vithas.”

The most advanced diagnostic imaging technology

The agreement includes the replacement of Vithas Group’s existing MR imaging equipment with Philips’ latest innovative MR systems, which stand out for their image quality and patient comfort, and because they do not consume helium, also stand out for their sustainability. Philips will also install hybrid operating room solutions, including its latest ceiling mounted live-image guidance system for minimally-invasive interventional therapy, allowing Vithas hospitals to perform many types of procedure with maximum precision and safety. Four new hybrid operating rooms will be installed across four of the group’s hospitals.

Next to this, Philips will replace the Vithas hospitals’ CT (Computed Tomography) equipment by high-end equipment, allowing them to perform more precise cardiac diagnoses thanks to the Philips equipment’s speed, coverage, and high image quality, while also minimizing radiation dose. The agreement also includes X-ray equipment, solutions for dose management, and a Corporate Network for Diagnostic Imaging.

Benefits of the Corporate Network for Diagnostic Imaging

Through this network, and thanks to a solution for reviewing, post-processing and sharing information from advanced medical imaging studies, more than 100 radiologists will be able to work in a unified way with access to tools that speed up and improve the quality of results. Likewise, more than 5,000 referring physicians will have higher quality radiological reports directly available to them via a clinical viewer. The solution will also improve the patient experience, because they will be able to view their reports and images from any PC or mobile device via a secure web portal.

Joint scientific research

The innovation and collaboration agreement between Philips and Vithas Group will make it possible for the two organizations to collaborate in technological innovation projects in Vithas Group reference centers. These projects will involve joint scientific research in key healthcare areas, as well as the training of Vithas Group professionals in new technologies and clinical procedures.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”